Josh Dubofsky

Silicon Valley
  • 140 Scott Drive
  • Menlo Park, CA 94025
  • USA

Josh Dubofsky is a partner in the Silicon Valley office of Latham & Watkins and a member of the Corporate Department. He joined Latham in 2001 and has practiced in the Silicon Valley and New York offices.

Mr. Dubofsky’s practice focuses on:

  • Mergers and acquisitions
  • Strategic corporate transactions and strategic planning
  • Public and private financing transactions
  • General corporate representation of both publicly traded and privately held companies

Mr. Dubofsky represents corporate clients, private equity firms and venture capital firms in acquisitions, divestitures and debt and equity investments across a wide range of industries, including:

  • Life sciences
  • Internet and digital media
  • Information technology
  • Retail and consumer products
  • Transportation
  • Financial services

Mr. Dubofsky also represents both public and private companies in general corporate governance matters and securities offerings, and provides legal advice and strategic planning assistance to management, directors and shareholders.

Mr. Dubofsky’s public and private mergers and acquisitions and strategic transaction practice has included representation of numerous companies, including: 

Healthcare and Life Sciences

  • Relypsa, Inc. in its US$1.5 billion sale to Galenica AG
  • Encore Vision in its US$465 million acquisition by Novartis AG
  • Kythera Biopharmaceuticals in its US$2.1 billion sale to Allergan plc
  • Alliance HealthCare Services in connection with the acquisition by Fujian Thai Hot Investment Co. of a majority of Alliance’s outstanding stock from Oaktree Capital and MTS Health Investors for US$102 million
  • Allergan in the US$40.5 billion sale of its Actavis Generics business to Teva
  • ArthroCare Corporation in its US$1.7 billion acquisition by Smith & Nephew
  • Conceptus, Inc. in its US$1.1 billion acquisition by Bayer AG
  • Medicis Pharmaceuticals in its acquisition by Valeant Pharmaceuticals for US$2.6 billion
  • Allos Therapeutics in its up to US$206 million acquisition by Spectrum Pharmaceuticals
  • ZymoGenetics in its US$885 million acquisition by Bristol-Meyers Squibb
  • Talon Therapeutics in its up to US$210 million acquisition by Spectrum Pharmaceuticals
  • A special committee of the board of directors of Genentech in the US$47 billion acquisition of the outstanding publicly held stock of Genentech by Roche
  • Plexxikon in its up to US$935 million acquisition by Daichi Sankyo
  • Thoratec in its proposed US$282 million acquisition of Heartware


  • IDT in its US$250 million acquisition of GigPeak 
  • eResearchTechnology, a Genstar Capital portfolio company, in its acquisition of PHT Corporation and in its sale to Nordic Capital
  • Netsmart, a Genstar Capital portfolio company, in its US$950 million sale to GI Partners and Allscripts
  • The independent directors of Rackspace Hosting in Rackspace’s US$4.3 billion acquisition by Apollo Global Management
  • Toshiba Corporation in its acquisition of OCZ Technology Group through a 363 bankruptcy sale process
  • A special committee of the board of directors of Google in the class C non-voting common stock recapitalization of Google
  • XP Power in its acquisition of EMCO High Voltage Corporation
  • OpenTable in its acquisition of Copilot Labs
  • Adobe Systems in its US$1.8 billion acquisition of Omniture
  • Gracenote in its sale to Sony for US$260 million
  • Narus in its acquisition by The Boeing Company
  • Intuit in its acquisition of Entellium through a 363 bankruptcy sale process

Transportation, Retail and Real Estate

  • US Airways in its US$17 billion merger with American Airlines
  • American Airlines in its US$200 million investment in China Southern Airlines
  • Troon Golf in its sale to Kohlberg & Company and Great White Shark Enterprises
  • Skechers USA in connection with the 3:1 split of its Class A and Class B common stock
  • Eddie Bauer in its 363 bankruptcy process sale to Golden Gate Capital for US$286 million
  • Guitar Center in its sale to Bain Capital for US$1.9 billion
  • The Rockefeller Group in its sale of Cushman & Wakefield to IFIL/Exor S.p.A.

Private Equity and Venture Capital

Mr. Dubofsky regularly represents private equity and venture capital firms in connection with private and public investments, acquisitions and divestitures.

Representative clients have included Technology Crossover Ventures, Spectrum Equity, KKR, Genstar Capital, The Carlyle Group and Weston Presidio, and recent matters include the representation of KKR in its investments in Ajax Health, BridgeBio, Cerêve, Signostics, Spirox and Slayback Pharma, Technology Crossover Ventures in public and private investments and divestitures of portfolio companies, including investments in, Netflix and MarketAxess and the sales of ExactTarget, Fiberlink, FX Alliance, iPipeline and XRS Corporation, Spectrum Equity in its acquisitions of ExactBid and PicMonkey, Indigo Partners in its acquisition of Frontier Airlines from Republic Airways, and Weston Presidio in the sale of its investments in Apple American Group, Star Manufacturing and The Wolf Organization.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.